Clover Biopharmaceuticals, Ltd.
2197.HK
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.32B
Close$
$0.24
86.5% downside
Current Fair Value
86.5% downsideOvervalued by 86.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.32 Billion |
|---|---|
| Enterprise Value | $2.23 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.16 |
| Beta | 2.58 |
| Outstanding Shares | 1,266,529,408 |
Return
| Return on Equity | 8.28% |
|---|---|
| Return on Assets | -27.42% |
| Return on Invested Capital | -1899.51% |
Valuation & Multiples
| P/E Ratio | 2.3 |
|---|---|
| PEG | -0.22 |
| Price to Sales | - |
| Price to Book Ratio | -1.79 |
| Enterprise Value to Revenue | 42.69 |
| Enterprise Value to EBIT | -1.88 |
| Enterprise Value to Net Income | -34 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 26, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
March 30, 2027
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Clover Biopharmaceuticals, Ltd.
257 employees
CEO: Joshua G. Liang Clover Biopharmaceuticals, Ltd. is a biotechnology enterprise focused on discovering, developing, and commercializing innovative vaccines and biological therapies. Their efforts target infectious diseases, various cancers, and autoimmune...